person
Bertrand C.
- Country
- France
- Department
- #3333:Endocrinology
Research Overview
assignment
19
Clinical Trials ·
- Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study
- Effect of Muvalaplin on Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: A Phase 3 Randomized Trial
- Inclisiran for Prevention of Major Adverse Cardiovascular Events in High-Risk Primary Prevention Patients with Atherosclerotic Cardiovascular Disease
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
751
Sites with multiple studies
Has run more than one trial at 751 of 1275 partner sites.
Specializations
Metabolic Liver Disorders
Specializes in investigating therapeutic approaches for non-alcoholic steatohepatitis (NASH) with particular focus on liver fibrosis treatment and novel combination therapies.
- Liver fibrosis management
- NASH resolution strategies
- Metabolic liver disease therapeutics
Cardiovascular Disease Prevention
Focuses on innovative treatments for atherosclerotic cardiovascular disease and hypercholesterolemia, including primary prevention strategies and lipid management.
- Major cardiovascular events prevention
- Lipid-lowering therapies
- Familial hypercholesterolemia treatment
Metabolic Disorders
Conducts research in Type 2 diabetes mellitus and severe hypertriglyceridemia, with emphasis on cardiovascular risk reduction in metabolic conditions.
- Diabetes management
- Triglyceride regulation
- Cardiovascular risk management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.